Target Name: MIR370
NCBI ID: G442915
Review Report on MIR370 Target / Biomarker Content of Review Report on MIR370 Target / Biomarker
MIR370
Other Name(s): mir-370 | hsa-miR-370-3p | microRNA 370 | hsa-mir-370 | MIRN370 | MicroRNA 370 | hsa-miR-370-5p

MIR370: A Potential Drug Target and Biomarker

Mir370, a non-coding RNA molecule, has been identified as a potential drug target and biomarker in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and various studies have suggested that it may play a crucial role in the development and progression of these diseases.

MIR370 is a part of the miRNA-21 (miR21) family, which is a well-known group of non-coding RNAs that regulate gene expression in various organisms, including humans. The miR21 family has been implicated in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the key features of MIR370 is its unique structure. It is a double-stranded RNA molecule, with a length of approximately 290 nucleotides. Its unique design consists of a core loop region, which is composed of 14 to 16 nucleotides, and a variable region, which is composed of 16 to 18 nucleotides. The variable region contains several putative binding sites that could interact with various protein molecules, leading to its potential as a drug target.

MIR370 has been shown to play a role in the development and progression of various diseases, including cancer. Several studies have shown that MIR370 is downregulated in various types of cancer, and its levels are often decreased in cancer cells compared to healthy cells. This suggests that MIR370 may be a useful biomarker for cancer diagnosis and treatment.

MIR370 has also been shown to be involved in the development and progression of neurodegenerative diseases. Studies have shown that MIR370 is downregulated in various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. This suggests that MIR370 may be a potential drug target for these diseases.

MIR370 has also been shown to be involved in the development and progression of autoimmune disorders. Studies have shown that MIR370 is downregulated in various autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. This suggests that MIR370 may be a potential drug target for these disorders.

In addition to its potential as a drug target, MIR370 has also been shown to have several potential biomarker properties. For example, several studies have shown that MIR370 is highly expressed in various tissues and fluids, including blood, urine, and brain. This suggests that MIR370 may be a potential biomarker for various diseases.

Furthermore, MIR370 has been shown to be involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. Studies have shown that MIR370 interacts with various proteins, including JKC1, a known regulator of cell apoptosis, and NF-kappa-B, a known regulator of inflammation. This suggests that MIR370 may be involved in the regulation of cellular processes that are important for the development and progression of various diseases.

In conclusion, MIR370 is a unique non-coding RNA molecule that has been identified as a potential drug target and biomarker in various diseases. Its unique structure and function have made it an attractive target for researchers to investigate, and various studies have suggested that it may play a crucial role in the development and progression of these diseases. Further research is needed to fully understand the role of MIR370 in these diseases and to develop effective treatments.

Protein Name: MicroRNA 370

The "MIR370 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR370 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR3713 | MIR3714 | MIR371A | MIR371B | MIR372 | MIR373 | MIR374A | MIR374B | MIR374C | MIR375 | MIR376A1 | MIR376A2 | MIR376B | MIR376C | MIR377 | MIR378A | MIR378B | MIR378C | MIR378D1 | MIR378D2 | MIR378E | MIR378F | MIR378G | MIR378H | MIR378I | MIR379 | MIR380 | MIR381 | MIR382 | MIR383 | MIR384 | MIR3907 | MIR3908 | MIR3909 | MIR3910-1 | MIR3910-2 | MIR3911 | MIR3912 | MIR3913-1 | MIR3913-2 | MIR3914-1 | MIR3914-2 | MIR3915 | MIR3916 | MIR3917 | MIR3918 | MIR3919 | MIR3920 | MIR3921 | MIR3922 | MIR3923 | MIR3924 | MIR3925 | MIR3926-1 | MIR3926-2 | MIR3927 | MIR3928 | MIR3929 | MIR3934 | MIR3935 | MIR3936 | MIR3936HG | MIR3937 | MIR3938 | MIR3939 | MIR3940 | MIR3941 | MIR3942 | MIR3943 | MIR3944 | MIR3945 | MIR3945HG | MIR3960 | MIR3972 | MIR3973 | MIR3974 | MIR3976 | MIR3976HG | MIR3977 | MIR3978 | MIR409 | MIR410 | MIR411 | MIR412 | MIR421 | MIR422A | MIR423 | MIR424 | MIR425 | MIR4251 | MIR4252 | MIR4253 | MIR4254 | MIR4255 | MIR4256 | MIR4257 | MIR4258 | MIR4259 | MIR4260 | MIR4261